Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.68 |
| ▸ | HTR1A | P08908 | 5/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | HTR1D | P28221 | 2/20 | 0.68 |
| ▸ | HTR1B | P28222 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
| ▸ | HTR6 | P50406 | 2/20 | 0.68 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.66 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724551 | 0.85 | GPR84 (0.69) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL9529083 | 0.84 | HTR2A (0.74) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL8252894 | 0.82 | HTR2A (0.76) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL29375720 | 0.81 | CYP2D6 (1.00) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| 5-Methoxytryptamine SCHEMBL29390103 | 0.81 | HTR1A (1.00) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| 5-Methoxytryptamine SCHEMBL41982 | 0.81 | HTR1A (1.00) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL676574 | 0.81 | CYP2D6 (1.00) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL7873256 | 0.81 | HTR2A (0.73) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL8120951 | 0.81 | HTR2A (0.73) | HTR2AHTR1ACYP2D6CYP1A2HTR1D | |
| SCHEMBL29736216 | 0.81 | HTR2A (0.73) | HTR2AHTR1ACYP2D6CYP1A2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1943245-A2 | 1,3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-5945440-A | Indolocarbazole imides and the use thereof | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PPARG, PPARA, PPARD | HTR2A 205/4885HTR1A 151/4885CYP2D6 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.